Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Trial Profile

Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 06 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 12 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
    • 12 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top